Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer.

Salman Rafi Punekar, Rochelle Castillo, Sabina Sandigursky, Daniel Chang Cho

Journal of immunotherapy (Hagerstown, Md. : 1997) 2021 Oct 01

filter terms:

Immune checkpoint inhibitors (ICIs) are a class of medications targeting mostly the PD-1/PD-L1 and CTLA-4 immune pathways in the treatment of many cancers. Despite the encouraging success of ICIs, they are associated with immune-related adverse events as well as exacerbation of underlying autoimmune conditions. The treatment of these conditions often involves discontinuation of ICI in addition to the utilization of immunomodulatory agents. In this report, we discuss a case in which a patient with metastatic renal cell carcinoma experienced exacerbation of underlying paraneoplastic dermatomyositis after treatment with ICI. He was successfully continued on ICI with the use of intravenous immunoglobulin. The patient experienced adequate control of his myositis but also experienced deepening of his antitumor response. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Salman Rafi Punekar, Rochelle Castillo, Sabina Sandigursky, Daniel Chang Cho. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2021 Oct 01;44(8):335-337